Serum leptin, resistin, visfatin and adiponectin levels in tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Cantarini, Luca ^a   Obici, Laura ^b   Simonini, Gabriele ^c   Cimaz, Rolando ^c   Bacarelli, Maria Romana ^a   Merlini, Giampaolo ^b   Vitale, Antonio ^a   Lucherini, Orso Maria ^a   Brizi, Maria Giuseppina ^a   Galeazzi, Mauro ^a   Fioravanti, Antonella ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adipokines; Adiponectin; Amyloidosis; Autoinflammatory disorders; Leptin; Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

Indexed keywords

ADIPONECTIN; COLCHICINE; ETANERCEPT; LEPTIN; METHOTREXATE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESISTIN; STEROID; ADIPOQ PROTEIN, HUMAN; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; RETN PROTEIN, HUMAN; TNFRSF1A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; AMYLOIDOSIS; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FEVER; GENDER; HUMAN; HUMAN CELL; MALE; MUTATION; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; HEREDITARY PERIODIC FEVER; MIDDLE AGED; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADIPONECTIN; ADULT; AGED; AMYLOIDOSIS; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; LEPTIN; MALE; MIDDLE AGED; MUTATION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHENOTYPE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RESISTIN; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84873284348     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. MASTERS SL, LOBITO AA, CHAE JJ, KASTNER DL Recent advances in the molecular pathogenesis of hereditary recurrent fevers. Curr Opin Allergy Clin Immunol 2006; 6: 428-33.
2. MCDERMOTT MF, AKSENTIJEVICH I, GALON J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
3. D'OSUALDO A, FERLITO F, PRIGIONE I et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54: 998-1008.
4. LOBITO AA, KIMBERLEY FC, MUPPIDI JR et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108: 1320-7.
5. AKSENTIJEVICH I, GALON J, SOARES M et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotypephenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 301-14.
6. CANTARINI L, LUCHERINI OM, BALDARI CT, LAGHI PASINI F, GALEAZZI M Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 2010; 28: 405-7.
7. CANTARINI L, LUCHERINI OM, CIMAZ R et al. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 2009; 22: 1051-8.
8. CANTARINI L, LUCHERINI OM, GALEAZZI M et al. Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 2009; 27: 890-1.
9. AGANNA E, HAMMOND L, HAWKINS PN et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48: 2632-44.
10. GATTORNO M, PELAGATTI MA, MEINI A et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516-20.
11. LAGO F, DIEGUEZ C, GÓMEZ-REINO J, GUALILLO O Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3: 716-24.
12. FIORAVANTI A, SIMONINI G, CANTARINI L et al. Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease. Rheumatol Int 2012; 32:1481-2.
13. CANTARINI L, SIMONINI G, FIORAVANTI A et al. Circulating levels of the adipokines vaspin and omentin in patients with juvenile idiopathic arthritis, and relation to disease activity. Clin Exp Rheumatol 2011; 29: 1044-8.
14. TILG H, MOSCHEN AR Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
15. MCMAHON M, SKAGGS BJ, SAHAKIAN L et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011; 70: 1619-24.
16. KLEIN-WIERINGA IR, VAN DER LINDEN MP, KNEVEL R et al. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011; 63: 2567-74.
17. LAGO F, GÓMEZ R, CONDE J, SCOTECE M, GÓMEZ-REINO JJ, GUALILLO O Cardiometabolic comorbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res (Hoboken) 2011; 63: 1083-90.
18. TOY B, TARÇIN O, BAǦCI S, USTÜNDAǦ Y, INAL A, Tiftikçi A Serum leptin is not a diagnostic marker for familial Mediterranean fever attacks. Mediators Inflamm 2006; 2006: 62868.
19. KISACIK B, EROL MF, YILMAZ G et al. Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis? Clin Rheumatol 2012; 31: 225-9.
20. KESKIN G, INAL A, OZIŞIK L Serum adiponectin levels in patients with familial Mediterranean fever. Protein Pept Lett 2010; 17: 1258-62.
21. GERDAN V, SARI I, KOZACI D et al. Downregulation of adiponectin in patients with familial Mediterranean fever during attack-free period. Rheumatol Int 2011; 32: 2819-22.
22. UGURLU S, SEYAHI E, CETINKAYA F, OZBAKIR F, BALCI H, OZDOGAN H Intima-media thickening in patients with familial Mediterranean fever. Rheumatology 2009; 48: 911-5.
23. YÜKSEL S, AYVAZYAN L, GASPARYAN AY Familial Mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J 2010; 4: 51-6.
24. LI L, YANG G, SHI S, YANG M, LIU H, BODEN G The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine 2009; 45: 12-9.
25. NOWLAN ML, DREWE E, BULSARA H et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 2006; 45: 31-7.
26. HENRY BA, CLARKE IJ Adipose tissue hormones and the regulation of food intake. J Neuroendocrinol 2008; 20: 842-9.
27. LA CAVA A, MATARESE G The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-9.
28. FINCK BN, JOHNSON RW Anti-inflammatory agents inhibit the induction of leptin by tumor necrosis factor-alpha. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1429-35.
29. WOZNIAK SE, GEE LL, WACHTEL MS, FREZZA EE Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-56.
30. OUCHI N, WALSH K Adiponectin as an antiinflammatory factor. Clin Chim Acta 2007; 380: 24e30
31. OUCHI N, KIHARA S, ARITA Y et al. Novel modulator of endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
32. OZGEN M, KOCA SS, DAGLI N, BALIN M, USTUNDAG B, ISIK A Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res 2010; 41: 457-63.
33. GUEBRE-EGZIABHER F, BERNHARD J, FUNAHASHI T, HADJ-AISSA A, FOUQUE D Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129-34.
34. POIRIER O, NICAUD V, GARIEPY J et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima- media thickness - the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet 2004; 12: 213-9.
35. STOJANOV S, DEJACO C, LOHSE P et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008; 67: 1292-8.
36. SÖDERBERG S, AHRÉN B, JANSSON JH et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-18.
37. BELTOWSKI J Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
38. WANNAMETHEE SG, WELSH P, WHINCUP PH et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil 2011; 18: 65-71.
39. SEYAHI E, YAZICI H Atherosclerosis in Bechet's syndrome. Clin Exp Rheumatol 2007; 25: S1-S5.
40. KALRA SP Pivotal role of leptin-hypothalamus signaling in the etiology of diabetes uncovered by gene therapy: a new therapeutic intervention? Gene Ther 2011; 18: 319-25
41. BUSSO N, KARABABA M, NOBILE M et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008; 3: e2267.